Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension

Erlic, Zoran; Reel, Parminder; Reel, Smarti; Amar, Laurence; Pecori, Alessio; Larsen, Casper K.; Tetti, Martina; Pamporaki, Christina; Prehn, Cornelia; Adamski, Jerzy; Prejbisz, Aleksander; Ceccato, Filippo; Scaroni, Carla; Kroiss, Matthias; Dennedy, Michael C.; Deinum, Jaap; Langton, Katharina; Mulatero, Paolo; Reincke, Martin; Lenzini, Livia; Gimenez-Roqueplo, Anne-Paule; Assie, Guillaume; Blanchard, Anne; Zennaro, Maria Christina; Jefferson, Emily und Beuschlein, Felix (2021): Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. In: Journal of Clinical Endocrinology & Metabolism, Bd. 106, Nr. 4: S. 1111-1128

Abstract

Context Identification of patients with endocrine forms of hypertension (EHT) (primary hyperaldosteronism [PA], pheochromocytoma/paraganglioma [PPGL], and Cushing syndrome [CS]) provides the basis to implement individualized therapeutic strategies. Targeted metabolomics (TM) have revealed promising results in profiling cardiovascular diseases and endocrine conditions associated with hypertension. Objective Use TM to identify distinct metabolic patterns between primary hypertension (PHT) and EHT and test its discriminating ability. Methods Retrospective analyses of PHT and EHT patients from a European multicenter study (ENSAT-HT). TM was performed on stored blood samples using liquid chromatography mass spectrometry. To identify discriminating metabolites a classical approach (CA) (performing a series of univariate and multivariate analyses) and a machine learning approach (MLA) (using random forest) were used. The study included 282 adult patients (52% female;mean age 49 years) with proven PHT (n = 59) and EHT (n = 223 with 40 CS, 107 PA, and 76 PPGL), respectively. Results From 155 metabolites eligible for statistical analyses, 31 were identified discriminating between PHT and EHT using the CA and 27 using the MLA, of which 16 metabolites (C9, C16, C16:1, C18:1, C18:2, arginine, aspartate, glutamate, ornithine, spermidine, lysoPCaC16:0, lysoPCaC20:4, lysoPCaC24:0, PCaeC42:0, SM C18:1, SM C20:2) were found by both approaches. The receiver operating characteristic curve built on the top 15 metabolites from the CA provided an area under the curve (AUC) of 0.86, which was similar to the performance of the 15 metabolites from MLA (AUC 0.83). Conclusion TM identifies distinct metabolic pattern between PHT and EHT providing promising discriminating performance.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0021-972X
• Sprache: Englisch